Výsledky vyhledávání - "Bettina Oxenius"

Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: A randomized, double-blind, placebo-controlled study of efficacy and tolerability

Autor: Lia, Gore, Sant, Chawla, Antonio, Petrilli, Molly, Hemenway, Debra, Schissel, Vickey, Chua, Alexandra D, Carides, Arlene, Taylor, Suzanne, Devandry, Jack, Valentine, Judith K, Evans, Bettina, Oxenius, Joanna L, Weinstein

Publikováno v: Pediatric Blood & Cancer. 52:242-247

Background The neurokinin-1 receptor antagonist aprepitant, plus a 5HT3 antagonist and corticosteroid is well-tolerated and effective in preventing chemotherapy-induced nausea and vomiting in adults but has not been formally assessed in adolescents.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fbb9f4f5b0d69c9f1e6253b5e9ddb40
https://doi.org/10.1002/pbc.21811

Zobrazit plný text záznamu

Peptic Ulcer and Bleeding Events Associated With Rofecoxib in a 3-Year Colorectal Adenoma Chemoprevention Trial

Autor: Jim Bolognese, Hui Quan, Dion Morton, Bettina Oxenius, Robert S. Bresalier, Susan Loftus, Robert S. Sandler, Yaron Niv, Angel Lanas, John A. Baron, Douglas J. Watson, Robert E. Schoen, Kevin J. Horgan, Carol A. Burke, Robert H. Ridell, Tomas J. Cook

Publikováno v: Gastroenterology. 132:490-497

BACKGROUND & AIMS: Our aim was to establish the incidence of symptomatic upper gastrointestinal ulcers, ulcer perforation, ulcer obstruction, or bleeding episodes (PUBs) associated with the use of selective cyclooxygenase-2 inhibitors at standard cli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4582a63a28da102f0710c0c3e254576e
https://doi.org/10.1053/j.gastro.2006.11.012

Zobrazit plný text záznamu

Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial

Autor: Angel Lanas, Christopher Lines, Dion Morton, Bettina Oxenius, Robert S. Sandler, Robert S. Bresalier, John A. Baron, Hui Quan, Marvin A. Konstam, James A. Bolognese, Kevin J. Horgan, Robert H. Riddell

Publikováno v: New England Journal of Medicine. 352:1092-1102

background Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but only limited long-term data have been available for analysis. We report on the cardiovascular outcomes associated with the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8d9942387f69872e6a38d22a44a186b
https://doi.org/10.1056/nejmoa050493

Zobrazit plný text záznamu

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events

Autor: Sean E. Harper, Hui Quan, Judith K. Evans, Michael Lee, Bettina Oxenius, Richard H. Hunt, Chang Yu, Douglas J. Watson

Publikováno v: The American Journal of Gastroenterology. 98:1725-1733

Etoricoxib is a selective cyclooxygenase inhibitor that in clinical studies has improved the signs and symptoms of osteoarthritis and rheumatoid arthritis and reduced the potential for GI injury. The incidence of endoscopically detected ulcers and of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e019c4d4d4439fec2c91ebcd9b6317a
https://doi.org/10.1111/j.1572-0241.2003.07598.x

Zobrazit plný text záznamu

A Randomized Trial of Rofecoxib for the Chemoprevention of Colorectal Adenomas

Autor: Kevin J. Horgan, Hui Quan, Robert H. Riddell, Susan Loftus, Robert S. Bresalier, James A. Bolognese, Angel Lanas, Bettina Oxenius, John A. Baron, Robert S. Sandler, Dion Morton

BACKGROUND & AIMS: In human and animal studies, nonsteroidal anti-inflammatory drugs have been associated with a reduced risk of colorectal neoplasia. Although the underlying mechanisms are unknown, inhibition of cyclooxygenase (COX), particularly CO

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::330ed219fde3eedfbae34ed9aba28d52